Today: 7 February 2026
Subscribe

Shan Ahmed Khan

As a journalist focused on finance and the stock market, he delivers fast, reliable, and easy-to-understand coverage of market news.

Scentre Group Sells 19.9% of Westfield Sydney to Australian Retirement Trust in A$864m Deal

Scentre Group Sells 19.9% of Westfield Sydney to Australian Retirement Trust in A$864m Deal

Scentre Group has agreed to sell a 19.9% stake in its flagship Westfield Sydney shopping centre to superannuation giant Australian Retirement Trust (ART) for A$864 million (about US$576 million), in a transaction priced at the asset’s June 2025 book value. Scentre will remain the majority owner and keep control of day-to-day operations, retaining an 80.1% interest and continuing as property, leasing and development manager. Scentre Group+1 On Wednesday, 24 December 2025, fresh details emerged on how ART plans to run the investment: Queensland-based institutional investor QIC will act as investment manager for ART’s new stake, while Scentre continues to manage
24 December 2025
····
Eos Energy Enterprises Stock (EOSE) Turns Volatile After Chair Transition News as Wall Street Reprices the 2026 Ramp

Eos Energy Enterprises Stock (EOSE) Turns Volatile After Chair Transition News as Wall Street Reprices the 2026 Ramp

Eos Energy Enterprises (NASDAQ: EOSE) is heading into the Christmas Eve session with fresh volatility on the tape. Shares closed Tuesday, December 23, 2025 at $11.96, down 7.21%, after the market digested a board leadership transition; pre-market indications early Wednesday, December 24 were modestly higher. With U.S. equities scheduled to close early at 1:00 p.m. ET on Dec. 24, thinner holiday liquidity can amplify price swings—especially for high-beta names like EOSE. StockAnalysis+1 What happened: Eos announces a board chair handoff effective year-end On December 22, 2025, Eos disclosed that Russ Stidolph, its non-executive Chair since 2018 and a long-time investor
24 December 2025
·····
Strategy Inc Stock MSTR News and Forecasts for December 24, 2025: Cash Reserve Pivot, Bitcoin Pause, and Wall Street Targets

Strategy Inc Stock MSTR News and Forecasts for December 24, 2025: Cash Reserve Pivot, Bitcoin Pause, and Wall Street Targets

December 24, 2025 — Strategy Inc (Nasdaq: MSTR) is spending Christmas Eve with investors debating a simple but loaded question: is the company’s latest move a prudent de-risking… or a sign that the “leveraged Bitcoin proxy” era is maturing into something more complicated? Shares have been volatile this week, trading around the high-$150s as the market digests fresh disclosures showing no new Bitcoin purchases during the latest reporting window and a sharply higher U.S. dollar cash reserve built from equity sales. MarketBeat+2MarketBeat+2 At the same time, Executive Chairman Michael Saylor is trying to reframe the entire investment story—positioning Strategy not
24 December 2025
·····
United States Antimony Corporation (UAMY) Stock: Today’s Move, Latest Contracts, Analyst Forecasts, and What Investors Are Watching on Dec. 24, 2025

United States Antimony Corporation (UAMY) Stock: Today’s Move, Latest Contracts, Analyst Forecasts, and What Investors Are Watching on Dec. 24, 2025

United States Antimony Corporation (NYSE American: UAMY) has become one of the most closely watched “critical minerals” stocks of 2025—partly because antimony has moved from obscure industrial input to strategic flashpoint, and partly because UAMY’s own contract wins and expansion plans have repeatedly jolted the share price. With U.S. markets trading through Wednesday, Dec. 24, 2025 (despite a federal-government closure order that didn’t change exchange schedules), liquidity and headlines are colliding in the classic year-end way: moves can look bigger, faster, and noisier than they would in mid-January. Reuters Below is what’s driving attention around UAMY stock today, what the
24 December 2025
·····
AiRWA Inc (YYAI) Stock News, Forecasts and Analysis for Dec. 24, 2025: New 10‑Q, $15.69M Offering, and Why the Tape Is So Volatile

AiRWA Inc (YYAI) Stock News, Forecasts and Analysis for Dec. 24, 2025: New 10‑Q, $15.69M Offering, and Why the Tape Is So Volatile

December 24, 2025 — AiRWA Inc. (NASDAQ: YYAI) heads into the Christmas Eve session with the kind of “small-cap-on-a-capital-raise” price action that tends to keep both momentum traders and long-term investors glued to Level II. After closing around $0.98 on Dec. 23, YYAI traded around $1.01 pre-market on Dec. 24 on some platforms, underscoring just how jumpy liquidity can be when fresh filings and financing news hit within the same week. StockAnalysis+1 That volatility also shows up in the stock’s extreme 52-week range reported by major data providers (roughly $0.8635 to $264.42). Importantly, those “high” numbers can look surreal after
24 December 2025
····
Broadcom (AVGO) Stock News Today, Forecasts and Analysis for Dec. 24, 2025: AI Margins, Tariffs, Insider Moves and Valuation

Broadcom (AVGO) Stock News Today, Forecasts and Analysis for Dec. 24, 2025: AI Margins, Tariffs, Insider Moves and Valuation

Broadcom Inc. (NASDAQ: AVGO) enters Christmas Eve trading with investors still debating the same two questions that have defined the stock’s volatile December: how durable is the AI-driven demand surge—and how much profitability gets sacrificed to capture it? With U.S. equities markets scheduled to close early at 1:00 p.m. ET today, liquidity is thinner than usual, which can exaggerate moves in high-momentum names like Broadcom. New York Stock Exchange+1 As of the latest available quote on Dec. 24, Broadcom shares were hovering around the $349–$350 area, after a strong prior session. MarketWatch Why Broadcom stock is still a headline name
24 December 2025
·····
Teva Stock News on Dec. 24, 2025: TEVA Rallies on S&P Credit Upgrade, $40 Price Target Hike, and Fresh Pipeline Catalysts

Teva Stock News on Dec. 24, 2025: TEVA Rallies on S&P Credit Upgrade, $40 Price Target Hike, and Fresh Pipeline Catalysts

Teva Pharmaceutical Industries Limited (NYSE: TEVA; TASE: TEVA) stock is finishing 2025 with unusual momentum for a company long labeled “just a generics maker.” On Dec. 24, 2025, TEVA is trading around the $31–$32 range after a sharp run-up over the past several weeks, with holiday-thinned markets now digesting a cluster of developments that bulls say strengthen Teva’s “pivot to growth” story—and bears say risk turning into a valuation trap. StockAnalysis+1 This is the key backdrop: credit conditions are improving, analysts are lifting targets, and Teva’s pipeline/biosimilars calendar is getting clearer—all while the company is still navigating the industry’s classic
24 December 2025
····
Rezolute, Inc. (RZLT) Stock News and Forecasts on Dec. 24, 2025: Phase 3 sunRIZE Miss, Analyst Target Cuts, and What Comes Next

Rezolute, Inc. (RZLT) Stock News and Forecasts on Dec. 24, 2025: Phase 3 sunRIZE Miss, Analyst Target Cuts, and What Comes Next

Rezolute, Inc. (Nasdaq: RZLT) is still in the spotlight on December 24, 2025, after a brutal mid-December selloff tied to its pivotal clinical trial news—and a wave of follow-on analyst downgrades, price-target resets, and investor-law-firm investigations. As of the latest available pricing around $2.42 per share, the stock is off its post-trial lows but remains dramatically below pre-readout levels, leaving investors weighing a simple question with complicated consequences: was sunRIZE a fatal blow, or a detour that shifts the story toward Rezolute’s next late-stage program? MarketBeat+1 Below is a complete, publication-ready breakdown of the current RZLT stock news, forecasts, and
24 December 2025
·····
Chick-fil-A Set to Return to Portland in Early 2026 at Former Strip Club Near Mall 205, as Christmas Eve Dining Hours Go Top of Mind

Chick-fil-A Set to Return to Portland in Early 2026 at Former Strip Club Near Mall 205, as Christmas Eve Dining Hours Go Top of Mind

PORTLAND, Ore. — December 24, 2025. On a day when millions of Americans are asking the same practical question — “What’s open on Christmas Eve and Christmas Day?” — Portland is also buzzing about a very different kind of food-and-hours headline: Chick-fil-A is preparing to return to Portland proper for the first time in roughly two decades, with an early 2026 opening now being touted for a high-profile site in Southeast Portland. KGW The new restaurant is slated for the former Venue Gentleman’s Club property on Southeast Stark Street, just north of Mall 205 — a location that has already
24 December 2025
Dollarama Stock (TSX: DOL) Near Fresh Highs on Dec. 24, 2025: Earnings Momentum, Global Expansion, and a Valuation Test

Dollarama Stock (TSX: DOL) Near Fresh Highs on Dec. 24, 2025: Earnings Momentum, Global Expansion, and a Valuation Test

Dollarama is ending 2025 in the spotlight as investors weigh a familiar question with an unusually sharp edge: how much is too much to pay for a business that keeps delivering? On December 24, 2025, the discussion is unfolding against a holiday-thinned trading session in Canada—markets are scheduled to close early—after the S&P/TSX set new records and heads toward its best annual performance since 2009. Reuters At the stock level, Dollarama has been pressing toward the upper end of its recent range, closing around C$204.69 in the latest session cited by multiple market trackers—right where the latest valuation commentary is
24 December 2025
·····
Reviva Pharmaceuticals (RVPH) Stock Plunges After FDA Calls for Second Phase 3 Trial: News, Forecasts, and Analyst Takeaways on Dec. 24, 2025

Reviva Pharmaceuticals (RVPH) Stock Plunges After FDA Calls for Second Phase 3 Trial: News, Forecasts, and Analyst Takeaways on Dec. 24, 2025

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) is in the spotlight on December 24, 2025 after a sharp selloff driven by a major regulatory development: the U.S. Food and Drug Administration recommended that Reviva run an additional Phase 3 trial for its lead schizophrenia candidate, brilaroxazine, before filing a New Drug Application (NDA). SEC+1 Shares were trading around $0.32 after the drop, reflecting how quickly biotech valuations can reprice when timelines and funding needs change—especially for micro-cap clinical-stage companies. StockAnalysis What happened to Reviva Pharmaceuticals stock on December 24, 2025? The core catalyst is a regulatory “reset” of the near-term approval
24 December 2025
·····
Regencell Bioscience Holdings Limited (RGC) Stock: News, Forecasts, and Fresh Analysis for Dec. 24, 2025

Regencell Bioscience Holdings Limited (RGC) Stock: News, Forecasts, and Fresh Analysis for Dec. 24, 2025

Dec. 24, 2025 — Regencell Bioscience Holdings Limited (NASDAQ: RGC) is having one of those “stock market is a strange animal” moments again: the share price is moving sharply on a story dominated less by traditional fundamentals and more by market structure—low float, extreme volatility, and ongoing legal overhang. As of Dec. 24, 2025, RGC was trading around $25.25, up roughly 14% on the day. Below is a complete, publication-ready roundup of what’s new today (12/24/2025), what the most current forecasts/models are implying, and what the latest filings and third‑party analysis say about the risks that keep following this stock
24 December 2025
·····
1 … 545 546 547 548 549 … 882

Stock Market Today

South32 share price drops 4% in ASX rout — what investors watch before results

South32 share price drops 4% in ASX rout — what investors watch before results

7 February 2026
South32 shares fell 4.1% to A$4.41 Friday as Australian miners dropped in the worst ASX session since April 2025. The S&P/ASX 200 lost 2%, erasing almost A$70 billion in value. South32’s half-year results and interim dividend decision are set for Feb. 12. Markets reopen Monday with investors watching for further volatility.
Wesfarmers share price: what to watch on ASX next week as results loom

Wesfarmers share price: what to watch on ASX next week as results loom

7 February 2026
Wesfarmers shares closed down 1.33% at A$85.04 on Friday, following a sharp drop in the S&P/ASX 200, which fell 2% for its steepest one-day loss in 10 months. Investors are watching for Australia’s household spending data next week and Wesfarmers’ half-year results due Feb. 19.
Go toTop